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Brain Lesion Volume and Capacity for Consent in
Stroke Trials
Potential Regulatory Barriers to the Use of Surrogate Markers
Krishna A. Dani, MRCP; Michael T. McCormick, MRCP; Keith W. Muir, MD, FRCP
Background and Purpose—European directives and legislation in some countries forbid inclusion of subjects incapable
of consent in research if recruitment of patients capable of consent will yield similar results. We compared brain lesion
volumes in stroke patients deemed to have capacity to consent with those defined as incapacitated.
Methods—Data were obtained from 3 trials recruiting patients primarily with cortical stroke syndromes. Patients were
recruited within 24 hours of onset and used MRI based selection or outcome criteria. Method of recruitment was
recorded with stroke severity, age, and brain lesion volumes on Diffusion Weighted Imaging.
Results—Of the 56 subjects included, 38 (68%) were recruited by assent and 18 (32%) by consent. The assent group had
a median lesion volume of 18.35 cubic centimetres (cc) (interquartile range [IQR] 8.27–110.31 cc), compared to 2.79
cc (IQR 1.31–12.33 cc) when patients consented (P0.0004). Lesions were smaller than 5 cc in 7/38 (18%) in the assent
group and 11/18 (61%) in the consent group (P0.0024). There was good correlation between neurological deficit by
NIH stroke scale score and lesion volume (r0.584, P0.0001). Logistic regression demonstrated NIHSS or lesion
volume predicted capacity to consent.
Conclusions—Patients with acute stroke who retain capacity to consent have significantly smaller infarct volumes than those
incapable of consent, and these are frequently below the limits where measurement error significantly compromises valid use
of volumetric end points. Only a small proportion of patients with capacity to consent would be eligible for, and contribute
usefully to, most acute stroke trial protocols. (Stroke. 2008;39:2336-2340.)
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The Declaration of Helsinki1 stipulates that patients whoare incapable of consent “. . . should not be included in
research unless the research is necessary to promote the
health of the population represented and this research cannot
instead be performed on legally competent persons.” This
allows for research participation by incapacitated individuals
provided that the interests of the patient group overall are best
served by such participation. However, the more recent
European Clinical Trials Directive (ECTD)2 stipulates that if
the “same results” could be achieved by recruitment of
persons who are capable of consent, then subjects should not
be recruited by assent. The position is further complicated by
locale-specific legal protections, such as the Adults With
Incapacity Act in Scotland,3 which states that the research
must provide “ real and direct benefit to the adult or to other
persons having the same incapacity.”
One fundamental issue regarding participation by acute stroke
patients in clinical trials is whether there are important differ-
ences between those with and without capacity to consent. If
there is no difference, then both the Declaration of Helsinki and
the ECTD advise that only those with capacity to consent should
be included. Demarquay and colleagues4 showed that capacity
diminishes with increasing age and baseline neurological deficit.
Similarly, data from the first 300 patients recruited to the third
International Stroke Trial (IST3)5 show that those with more
severe stroke were less likely to have been recruited by consent,
with clinical syndrome being an important determinant.
Brain imaging is increasingly included as a biomarker of
treatment effect in clinical trials, and trials designed with
imaging end points generally include imaging selection cri-
teria. We hypothesized that imaging based trials, and indeed
most acute stroke trials, would be significantly compromised
if recruitment were restricted to subjects who retain capacity.
We therefore assessed the lesion volumes from patients
included in 3 studies of acute stroke at our institution and
compared the volumes in those who had been recruited by
consent to those recruited by assent.
Methods
Studies
Three acute stroke studies that used magnetic resonance imaging (MRI)
in our institution were identified. All studies had been approved by local
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or national Research Ethics Committees. Studies 1 and 2 were con-
ducted after the ECTD and local legislation on Adults with Incapacity,
while study 3 predated these. Studies 1 and 2 were single-site, imaging-
based studies, whereas study 3 was a multi-center neuroprotectant trial.
All 3 studies recruited patients primarily with cortical stroke syndromes,
whereas Study 3 also included subjects with lacunar syndromes. Studies
1 and 2 performed scans within 24 hours and study 3 scanned patients
within 12 hours of ictus. Scans were performed using either a 1.5T
or a 3T MRI scanner. All 3 studies permitted recruitment either by
consent or by assent from relatives. The capacity of individual
subjects was assessed only by the randomizing clinician. Consent or
assent was obtained in all cases by an experienced stroke neurologist,
physician, or research fellow, with the most senior investigator
involved being recorded. Patients from these studies were included if
digital copies of the initial MRI scans were available for review.
Medical files for these patients were retrieved, and data describing
the recruitment method, baseline demographic data, and neurological
deficit were recorded.
Clinical Data
The following data were recorded for each individual: age, sex, stroke
lateralization, clinical syndrome using the Oxfordshire Community
Stroke Project (OCSP),6 stroke severity by the National Institutes of
Health Stroke Scale (NIHSS),7 time to imaging, and whether or not an
individual was treated with recombinant tissue Plasminogen Activator
(rt-PA).
Image Analysis
Lesion volumes on admission were retrospectively assessed by 2
individuals; M.T.M. (Studies 2 and 3) and K.A.D. (study 1). The
software package Cheshire (Perceptive Informatics, PAREXEL) was
used to calculate lesion volumes on diffusion weighted imaging
(DWI) sequences. After identification of the lesion by the rater, a
semiautomated method was used to define lesion borders on each
slice. Further manual refinement on each slice produced final lesion
boundaries. The lesion volume was then calculated automatically.
Where available, formal reports of angiographic examinations (CT
angiography and time of flight magnetic resonance angiography) by
experienced neuroradiologists were reviewed and the site of any
occlusion noted. Results of perfusion imaging, when undertaken,
were also assessed.
Statistical Analysis
Statistical analyses were mainly performed with Minitab (Version
14.0). The distribution of data were assessed using a Kolmogorov–
Smirnov Test, and a Mann–Whitney test was subsequently used to
investigate whether lesion volumes in the group recruited by assent
differed from those of the group recruited by consent. Spearman’s
Rank test was used to assess the correlation between admission
NIHSS score and lesion volume. A number of other clinical parameters
were compared between groups (Table). Finally a binary logistic
regression analysis was performed to determine the effects of
NIHSS, lesion volume, age, and lateralization on the capacity to
consent (SPSS v14.0).
Results
Baseline Data
Scans from 56 patients were analyzed. Thirty-eight patients
(68%) were recruited by assent and 18 patients (32%) by
consent. Studies 1, 2, and 3 contributed 15, 29, and 12 patients,
respectively, with 33%, 21%, and 58% of patients being re-
cruited by consent in these studies. Baseline characteristics for
the assenting and consenting groups are given in the Table.
Four investigators were involved: K.M. recruited 13,
M.T.M. recruited 25, K.A.D. recruited 14. One other inves-
Table. Baseline Data in Each Group
Assent Group Consent Group Differences Between Groups (P Value)
Total No. of patients (% of total) 38 (68%) 18 (32%)   
Mean age, SD 7111.2 6812.7 0.398 (Mann–Whitney)
Mean time to imaging, SD 17.17.1 14.37.3 0.143 (Mann–Whitney)
No. of patients receiving rtPA (% of group) 10 (26%) 2 (11%) 0.2168 (Fisher Exact)
Mean time to rtPA, minsSD 16623 1773.5 0.564 (Mann–Whitney)
Clinical syndrome, No. of patients (%)
TACS 20 (53%) 3 (17%) 0.0231*
PACS 11 (29%) 9 (50%) (Fisher-Freeman-Halton Exact)
LACS 5 (13%) 6 (33%)
POCS 2 (5%) 0 (0%)
Site of occlusion
ICA 3 0 0.594
M1, MCA 5 1 (Fisher-Freeman-Halton Exact)
M2, MCA 1 1
PCA 1 1
Unidentified 13 6
Left:right hemisphere stroke 11:7 20:17 0.638 (Chi2)
Lesions 5 cc (%) 11/18 (61%) 7/38 (18.4%) 0.0024 (Chi2)
Median lesion volume (cc) IQR 18.35 (8.27–110.3) 2.79 (1.31–12.33) 0.0004 (Mann–Whitney)
The differences in clinical syndrome between the groups are statistically significant (P0.0231, Fisher-Freeman-Halton Exact Test).
The site of occlusion is also documented for all cases where angiography was performed.
TACS indicates total anterior circulation stroke; PACS, partial anterior circulation stroke; LACS, lacunar stroke; POCS, posterior
circulation stroke; ICA, internal carotid artery; MCA, middle cerebral artery; PCA, posterior cerebral artery; cc, cubic centimeters. Note
1 patient in the Assent group had bilateral lesions.
*Statistically significant, P0.05.
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tigator recruited only 1 patient, and data regarding recruiting
investigator were not available for 3 patients. Among the 3
main recruiting investigators there were no differences in lesion
volume (P0.15 Kruskal-Wallis), the proportions recruited by
assent (46% 6⁄13, 80% 20⁄25, and 71% 10⁄14; P0.118, Fisher-
Freeman-Halton Exact test), the proportion with left hemi-
sphere strokes (P0.506, Fisher Freeman Halton), or of
median NIHSS score (P0.800, Kruskal–Wallis). There was
no significant difference in lesion volume (P0.6511, Mann–
Whitney) or median NIHSS (P0.1528, Mann–Whitney)
between those with right hemisphere strokes compared with
those with left hemisphere strokes. Perfusion imaging (PWI)
was available for 7 patients, of whom none had PWI–DWI
mismatch, consistent with the late imaging time in most
cases.
The distribution of clinical syndromes defined by OCSP
criteria differed significantly between groups (Table; P0.0231,
Fisher-Freeman-Halton Exact test). There was a trend toward
more proximal occlusion in the assenting group but this did
not reach statistical significance (P0.594, Fisher-Freeman-
Halton Exact).
Lesion Volume in Assent and Consent Groups
Lesion volume data were not of normal distribution (P0.010,
Kolmogorov-Smirnov) and were positively skewed. The as-
senting group had a median lesion volume of 18.35 cubic
centimetres (cc) (interquartile range [IQR] 8.27 to 110.31 cc)
and a mean (SD) of 63.7 cc (78.5). In the consenting
group, the median lesion volume was 2.79 cc (IQR 1.31 to
12.33 cc) with a mean (SD) of 12.1 cc (23.1). Lesion
volumes of assenting patients were significantly greater than
those of consenting patients (upper tailed Mann–Whitney
test, P0.0004). Statistical significance remained when the
14 patients treated with rt-PA were excluded to ensure that
there was no confounding effect of reperfusion (P0.002;
n42): mean, median, and IQR volumes were 66 cc, 16.9 cc,
and 8.6 to 118 cc for the assenting group and 7.9 cc, 3.6 cc,
and 1.8 to 9.9 cc for the consenting group.
Predictive Factors for Capacity to Consent
There was a positive correlation between NIHSS and lesion
volume (Figure; n42, Spearman Rank Correlation coeffi-
cient r0.584; P0.0001). When patients who received
rt-PA were excluded from this analysis, the correlation was
similar (n32, r0.587, P0.001). Follow-up NIHSS data
were available for 34 patients; 2 patients at day 3 and 32
patients at day 7. There was no difference in lesion volumes
between those patients who demonstrated an improvement in
NIHSS 40% (14 patients) compared to those who did not
(P0.20, Mann–Whitney, n20).
In a binary logistic regression model to predict capacity to
consent, including lesion volume, stroke lateralization, age,
and NIHSS, the only significant univariate predictor was
NIHSS (n38, P0.017). Lesion volume was of borderline
significance (n55, P0.052). When both NIHSS and lesion
volume were included in the model, only NIHSS was signif-
icant (n38, odds ratio 0.13 [95% confidence interval 0.23 to
0.742] per 4 point increase in NIHSS score, P0.022).
Discussion
Our findings support the need to recruit patients to trials by
assent. We found significant differences in lesion volume,
stroke severity, and clinical syndrome between those recruited
by consent compared to those recruited by assent. Unsurpris-
ingly we demonstrated that NIHSS is the best predictor of
capacity to consent.
Two central ethical questions prompted by considering the
application of the European Clinical Trials Directive in acute
stroke trials are (1) whether there are reasons to expect
differences in the biology of stroke in those able to consent
from those recruited by assent that would compromise the
end points for a trial; and (2) whether there are other practical
issues that prevent clinically useful data being obtained from
consenting patients. Imaging has the potential to identify the
most appropriate subset of patients for recruitment, meaning
fewer subjects may be required to produce informative data.8
However, it will be additionally important to know whether
capacity for consent might signify a different biological
response. Current indirect data suggest it does. For example,
admission lesion volume is an independent predictor of
intracerebral hemorrhage after the administration of intrave-
Figure. Scatterplot showing the relation-
ship of NIHSS to lesion volume. Open
circles represent the “consent” group,
and black circles represent the “assent”
group. The vertical black line represents
the lower NIHSS threshold for the inclu-
sion criteria in some stroke studies, eg,
DEFUSE.
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nous thrombolytic therapy,9 suggesting an increased risk in
patients in the assenting group. In those patients deemed
capable of consent, we found a predominance of lacunar
syndromes, and distal MCA occlusions associated with lesser
neurological deficit. Therefore this cohort is unlikely to
provide useful data regarding reperfusion or recanalization.
Many of these patients are likely to improve spontaneously,
unlike the larger strokes seen in the assent group. Therefore it
is clear that significant differences exist in stroke etiology,
presentation, natural history, and prognosis between consent-
ing and assenting groups, and conclusions made from one
cohort may not be applicable to the other.
With regard to the second issue, to find evidence of a
biological effect, either by change in neurological impair-
ment or by lesion volume, the test instruments used must
be sensitive to the degree of change expected. Exclusion of
patients with brain lesion volumes under 5 cc has been
proposed because measurement error is too great to produce
reliable results.10 If a change in radiological parameters is not
measurable reliably, recruitment of a subject might be re-
garded as ethically dubious, irrespective of an individual’s
capacity. Of note, only 13% of patients recruited by assent
had lesion volumes less than 5 cc, suggesting that even
measurement error in imaging-based trials may be less in the
assenting group.
What would have been the effect in our center of restricting
recruitment to patients capable of consent? Typical inclusion
criteria for imaging-based trials include both clinical mea-
sures of stroke severity selection and lesion size.10–14 If
criteria such as minimum NIHSS score of 6 (as used in
DEFUSE11) and minimum lesion volume of 5 cc (to reduce
measurement error10) were applied to our population, recruit-
ment by consent alone would have resulted in only 4 patients
(7%) being included, all of whom still had relatively small
lesions (20 cc). Of the remaining 28 patients where NIHSS
data were available, 25 of these could also be included if
assent was allowed. Therefore, if assent were not possible
recruitment of the remaining eligible patients would allow
only limited conclusions to be made, thus potentially leading
to a situation of unethical recruitment of these “eligible”
patients. Many stroke trials which are not primarily imaging-
based also specify a minimum neurological deficit (NIHSS)
for inclusion, and thus these issues are applicable to stroke
trials in general.
The validity of consent is questionable in neurological
disease and in acute illness. Even acute stroke patients
eligible for thrombolysis who recover rapidly have limited
recall of the nature of their event,15 and in subarachnoid
hemorrhage trials only 28% of patients felt that they had been
capable of making an adequate decision.16 In this regard it is
vital that the information sheets provided to patients in acute
trials are clear and concise and aimed at patients with little
medical knowledge.
Our findings relate to practice at a single site but behavior
with respect to consent appeared reasonably consistent across
a number of different investigators and studies, although
clearly all were practicing in the same environment. Our site
is experienced in recruitment to clinical trials in acute stroke
and has not noted any substantial differences in interpretation
of recruitment processes compared to other sites in any
multicenter trial. The population described here is fairly
typical of those in stroke trials.
We did not assess lesion localization or morphology. Our
cohort is not entirely homogeneous with minor differences in
time window of recruitment and clinical syndromes permitted
between studies. We cannot exclude the possibility that knowl-
edge of lesion volume might have influenced the decision
regarding appropriate means of recruitment, but MRI was
seldom used as the primary imaging modality during the
period of these studies. We did not have repeated data on
vessel occlusion or perfusion status, but findings remained
significant after excluding rt-PA–treated patients whose
initial NIHSS score may not have reflected accurately the
DWI lesion volume attributable to reperfusion before
imaging.
In conclusion, this study demonstrates that lesion volumes
are greater in patients recruited to acute stroke studies by
assent compared to consent. Given the biological and clinical
differences between small and large lesions, and the method-
ological restrictions imposed by small lesions, this empha-
sizes the importance of recruitment by assent to many acute
stroke studies. Neither safety nor efficacy outcomes may be
measurably reliable from consenting patients alone, with
effects on sample size, study duration, and validity of
conclusions that may have a wider and potentially negative
impact.
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